vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and WORKIVA INC (WK). Click either name above to swap in a different company.
WORKIVA INC is the larger business by last-quarter revenue ($238.9M vs $177.4M, roughly 1.3× Pacira BioSciences, Inc.). WORKIVA INC runs the higher net margin — 4.9% vs 1.6%, a 3.3% gap on every dollar of revenue. On growth, WORKIVA INC posted the faster year-over-year revenue change (19.5% vs 5.0%). Over the past eight quarters, WORKIVA INC's revenue compounded faster (16.6% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Workiva, Inc. is a global software-as-a-service (SaaS) company. It provides a cloud-based connected and reporting compliance platform that enables the use of connected data and automation of reporting across finance, accounting, risk, and compliance.
PCRX vs WK — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $238.9M |
| Net Profit | $2.9M | $11.8M |
| Gross Margin | — | 80.7% |
| Operating Margin | 3.9% | 3.3% |
| Net Margin | 1.6% | 4.9% |
| Revenue YoY | 5.0% | 19.5% |
| Net Profit YoY | — | 234.0% |
| EPS (diluted) | $0.07 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $238.9M | ||
| Q3 25 | $179.5M | $224.2M | ||
| Q2 25 | $181.1M | $215.2M | ||
| Q1 25 | $168.9M | $206.3M | ||
| Q4 24 | $187.3M | $199.9M | ||
| Q3 24 | $168.6M | $185.6M | ||
| Q2 24 | $178.0M | $177.5M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $11.8M | ||
| Q3 25 | $5.4M | $2.8M | ||
| Q2 25 | $-4.8M | $-19.4M | ||
| Q1 25 | $4.8M | $-21.4M | ||
| Q4 24 | — | $-8.8M | ||
| Q3 24 | $-143.5M | $-17.0M | ||
| Q2 24 | $18.9M | $-17.5M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 80.7% | ||
| Q3 25 | 80.9% | 79.3% | ||
| Q2 25 | 77.4% | 77.0% | ||
| Q1 25 | 79.7% | 76.6% | ||
| Q4 24 | 78.7% | 77.1% | ||
| Q3 24 | 76.9% | 76.5% | ||
| Q2 24 | 75.1% | 76.8% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 3.3% | ||
| Q3 25 | 3.5% | -1.5% | ||
| Q2 25 | 4.7% | -10.3% | ||
| Q1 25 | 1.2% | -12.0% | ||
| Q4 24 | 13.2% | -6.7% | ||
| Q3 24 | -82.8% | -11.7% | ||
| Q2 24 | 15.9% | -13.0% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | 3.0% | 1.2% | ||
| Q2 25 | -2.7% | -9.0% | ||
| Q1 25 | 2.8% | -10.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | -85.1% | -9.2% | ||
| Q2 24 | 10.6% | -9.9% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.21 | ||
| Q3 25 | $0.12 | $0.05 | ||
| Q2 25 | $-0.11 | $-0.35 | ||
| Q1 25 | $0.10 | $-0.38 | ||
| Q4 24 | $0.38 | $-0.15 | ||
| Q3 24 | $-3.11 | $-0.31 | ||
| Q2 24 | $0.39 | $-0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $338.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $-5.4M |
| Total Assets | $1.2B | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $338.8M | ||
| Q3 25 | $246.3M | $315.9M | ||
| Q2 25 | $445.9M | $284.3M | ||
| Q1 25 | $493.6M | $242.0M | ||
| Q4 24 | $484.6M | $301.8M | ||
| Q3 24 | $453.8M | $248.2M | ||
| Q2 24 | $404.2M | $267.9M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-5.4M | ||
| Q3 25 | $727.2M | $-36.9M | ||
| Q2 25 | $757.8M | $-66.5M | ||
| Q1 25 | $798.5M | $-75.7M | ||
| Q4 24 | $778.3M | $-41.7M | ||
| Q3 24 | $749.6M | $-50.8M | ||
| Q2 24 | $879.3M | $-77.7M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.6B | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $51.0M |
| Free Cash FlowOCF − Capex | — | $50.7M |
| FCF MarginFCF / Revenue | — | 21.2% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $138.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $51.0M | ||
| Q3 25 | $60.8M | $46.2M | ||
| Q2 25 | $12.0M | $50.3M | ||
| Q1 25 | $35.5M | $-7.4M | ||
| Q4 24 | $33.1M | $44.0M | ||
| Q3 24 | $53.9M | $18.9M | ||
| Q2 24 | $53.2M | $-14.0K |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $50.7M | ||
| Q3 25 | $57.0M | $46.1M | ||
| Q2 25 | $9.3M | $49.3M | ||
| Q1 25 | $26.9M | $-8.1M | ||
| Q4 24 | $31.0M | $43.2M | ||
| Q3 24 | $49.8M | $18.7M | ||
| Q2 24 | $51.6M | $-122.0K |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 21.2% | ||
| Q3 25 | 31.7% | 20.5% | ||
| Q2 25 | 5.1% | 22.9% | ||
| Q1 25 | 15.9% | -3.9% | ||
| Q4 24 | 16.6% | 21.6% | ||
| Q3 24 | 29.6% | 10.1% | ||
| Q2 24 | 29.0% | -0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 2.2% | 0.0% | ||
| Q2 25 | 1.5% | 0.5% | ||
| Q1 25 | 5.1% | 0.4% | ||
| Q4 24 | 1.1% | 0.4% | ||
| Q3 24 | 2.4% | 0.1% | ||
| Q2 24 | 0.9% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.31× | ||
| Q3 25 | 11.20× | 16.57× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
WK
| License And Service | $219.3M | 92% |
| XBRL Professional Services | $16.4M | 7% |
| Other Services | $3.2M | 1% |
